

REFERENCES

- Ahmad, A., Shahabuddin, S., Sheikh, S., Kale, P., Krishnappa, M., Rane, R. C., & Ahmad, I. (2010). Endoxifen, a New Cornerstone of Breast Cancer Therapy: Demonstration of Safety, Tolerability, and Systemic Bioavailability in Healthy Human Subjects. *Clinical pharmacology and therapeutics*, 88, 814–817.
- American Cancer Society. (2015). *Cancer Facts and Statistics*. Retrieved October 14, 2016, from <http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-046381.pdf>
- Anders, C. K., Johnson, R., Litton, J., Phillips, M., & Bleyer, A. (2009). Breast cancer before age 40 years. *Seminars in Oncology*, 237-249.
- Awolarana, O., Brooks, S. A., & Lavender, V. (2016). Breast cancer osteomimicry and its role in bone specific metastasis; an integrative, systematic review of preclinical evidence. *The Breast*, 30, 156-171.
- Banerjee, S. K. (2011). Hormonal Carcinogenesis. In *Encyclopedia of Cancer* (pp. 1730-1733). Berlin: Springer Berlin Heidelberg.
- Blows, F. M., Driver, K. E., K, S. M., Broeks, A., & van Leeuwen, F. E. (2010). Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. *PLoS Med*, 7(5), e1000279.
- Bustreo, S., Osella-Abate, S., Cassoni, P., Donadio, M., Airoldi, M., Pedani, F., . . . Castellano, I. (2016). Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up. *Breast Cancer Res Treat*, 157, 363-371.
- Cheang, M., Martin, M., Nielsen, T., & Prat, A. (2015). Defining breast cancer intrinsic subtypes by quantitative receptor expression. *Oncologist*, 20, 474-482.

- Colleoni, M., Rotmensz, N., Robertson, C., & Orlando, L. (2002). Very young women (<35 years) with operable breast cancer: features of disease at presentation. *Annals of Oncology*, 13(2), 273-279.
- Daniel, A. R., Hagan, C. R., & Lange, C. A. (2011). Progesterone receptor action: defining a role in breast cancer. *Expert Rev Endocrinol Metab*, 6(3), 359-369.
- Dorland, W. N. (2011). *Dorland's Medical Dictionary* (32nd ed.). Philadelphia: Elsevier.
- Effi, A. B., Aman, N. A., Kouli, B. S., Koffi, K. D., Traore, Z. C., & Kouyate, M. (2016). Breast Cancer Molecular Subtypes Defined by ER/PR and HER2 Status: Association with Clinicopathologic Parameters in Ivorian Patients. *Asian Pacific Journal of Cancer*, 17(4), 1973-1978.
- Farouk, O., Ebrahim, M. A., Senbel, A., Emarah, Z., Abozeed, W., Seisa, M. O., . . . Abdelhady, S. (2016). Breast cancer characteristics in very young Egyptian women <35 years. *Breast Cancer: Targets and Therapy*, 8, 53-58.
- Filardo, E. J. (2017). A role for G-protein coupled estrogen receptor (GPER) in estrogen-induced carcinogenesis: Dysregulated glandular homeostasis, survival and metastasis. *J Steroid Biochem Mol Biol*, S0960-0760.
- Gabriel, A. (2016). *Breast Anatomy*. Retrieved October 25, 2016, from <http://reference.medscape.com/article/1273133-overview#a3>
- Galukande, M., Wabinga, H., Mirembe, F., Karamagi, C., & Asea, A. (2014). Molecular breast cancer subtypes prevalence in an indigenous Sub Saharan African population. *The Pan African Medical Journal*, 17, 249.
- Gnerlich, J. L., Deshpande, A. D., Jeffe, D. B., & Sweet, A. (2009). Elevated Breast Cancer Mortality in Young Women (<40 Years) Compared with Older Women Is Attributed to Poorer Survival in Early Stage Disease. *Journal of the American College of Surgeons*, 208(3), 341-347.

- Greene, F. L., Page, D. L., Fleming, I. D., Fritz, A. G., Balch, C. M., Haller, D. G., & Morrow, M. (2002). *AJCC Cancer Staging Manual* (6th ed.). Philadelphia: AJCC.
- Guisse, T., Kozlow, W., Heras-Herzig, A., Padalecki, S., Yin, J., & Chirgwin, J. (2005). Molecular mechanism of breast cancer metastasis to the bone. *Clin Breast Cancer*, 5, s46-s53.
- Hammond, M. E., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., & Badve, S. (2010). American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. *Journal of Clinical Oncology*, 28(16), 2784-95.
- Hartaningsih, N. M., & Sudarsa, I. W. (2013). Kanker Payudara pada Wanita Usia Muda di Bagian Bedah Onkologi Rumah Sakit Umum Pusat Sanglah Denpasar Tahun 2002 – 2012.
- Hennigs, A., Riedel, F., Gondos, A., Sinn, P., Schirmacher, P., Marmé, F., & Jäger, D. (2016). Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study. *BMC Cancer*, 16, 734.
- Hunter, K. W., Crawford, N. P., & Alsarraj, J. (2008). Mechanisms of metastasis. *Breast Cancer Research*, 10(Supplement 1), S2.
- Ihemelandu, C., Leffall, L. J., Dewitty, R., Naab, T., & Mezghebe, H. (2007). Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. *Journal of Surgical Research*, 143(1), 109-118.
- International Agency for Research on Cancer. (2012). *Breast Cancer Estimated Incidence, Mortality and Prevalence Worldwide in 2012*. Retrieved July 17, 2017, from <http://globocan.iarc.fr/old/FactSheets/cancers/breast-new.asp>
- Kumar, V., Abbas, A. K., & Aster, J. C. (2013). *Robbins Basic Pathology* (9th ed.). Philadelphia: Elsevier Saunders.

- Kumar, V., Abbas, A. K., Fausto, N., & Aster, J. C. (2010). *Robbins and Cotran Pathologic Basis of Disease* (8th ed.). Philadelphia: Saunders Elsevier.
- Lakhani, S., Ellis, I., SJ, S., Tan, P., & van de Vijver, M. (. (2012). *WHO Classification of Tumours of the Breast*. Lyon: IARC.
- Lu, X., & Kang, Y. (2007). Organotropism of breast cancer metastasis. *J Mammary Gl Biol Neoplasia*, 12, 153-162.
- Margan, M. M., Jitariu, A. A., Cimpean, A. M., Nica, C., & Raica, M. (2016). Molecular Portrait of the Normal Human Breast Tissue and Its Influence on Breast Carcinogenesis. *Journal of Breast Cancer*, 19(2), 99–111.
- Murad, T. (1971). A proposed histochemical and electron microscopic classification of human breast. *Cancer*, 27, 288.
- Onitilo, A. A., Engel, J. M., Greenlee, R. T., & Mukesh, B. N. (2009). Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival. *Clinical Medicine and Research*, 7(1), 4-13.
- Pérez-Rodríguez, G., Aranda-Moreno, C., Olivares-Corichi, I., & Garcia-Sanchez, J. (2015). The association of subtypes of breast cancer with tumour characteristics and reproductive factors in 1326 Mexican women. *Contemporary Oncology*, 19(6), 462-466.
- Rakha, E. A., Reis-Filho, J. S., Baehner, F., & Dabbs, D. J. (2012). Breast cancer prognostic classification in the molecular era: the role of histological grade. *Breast Cancer Research*, 12(4), 207.
- Rakha, E. A., Reis-Filho, J. S., Baehner, F., Dabbs, D. J., & Decker, T. (2010). Breast cancer prognostic classification in the molecular era: the role of histological grade. *Breast Cancer Res*, 12(4), 207.
- Roychowdhury, M. (2016). *Mixed ductal and lobular carcinoma*. Retrieved July 21, 2017, from <http://www.pathologyoutlines.com/topic/breastmalignantmixedductallobular.html>

- Shah, R., Rosso, K., & Nathanson, S. D. (2014). Pathogenesis, prevention, diagnosis and treatment of breast cancer. *World Journal of Clinical Oncology*, 5(3), 283-298.
- Stingl, J., & Caldas, C. (2007). Molecular heterogeneity of breast carcinomas and the cancer stem cell. *Nature Reviews Cancer*, 10, 791.
- Thangjam, S., Laishram, R. S., & Debnath, K. (2014). Breast carcinoma in young females below the age of 40 years: A histopathological perspective. *South Asian Journal of Cancer*, III(2), 97-100.
- Way, T.-D., & Lin, J.-K. (2005). Role of HER2/HER3 co-receptor in breast carcinogenesis. *Future Oncol*, 1(6), 841-849.
- Widodo, I., Dwianingsih, E., Triningsih, E., & Utoro, T. (2014). Clinicopathological Features of Indonesian Breast Cancers with Different Molecular Subtypes. *Asian Pacific Journal of Cancer Prevention*, 15(15), 6109-13.
- Winchester, D. (1996). Breast cancer in young women. *Surgical Clinical of North America*, 76(2), 279-87.
- Wolff, A. C., Hammond, M. E., Schwartz, J. N., Hagerty, K. L., & Allred, D. C. (2007). American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. *Journal of Clinical Oncology*, 25(1), 118-45.
- Wolf-Yadlin, A., Kumar, N., Zhang, Y., Hautaniemi, S., Zaman, M., Kim, H.-D., . . . White, F. M. (2006). Effects of HER2 overexpression on cell signaling networks governing proliferation and migration. *Mol Syst Biol*, 2(1), 54.
- World Health Organization. (2013). Global burden raises to 14.1 million new cases in 2012: Marked increase in breast cancer must be addressed. *Latest world cancer statistics* (p. 1). Geneva: World Health Organization.